Protein phosphatases in systemic autoimmunity-Immunometabolism-CSCIED科技核心评价数据库-手机版

Protein phosphatases in systemic autoimmunity

Protein phosphatases in systemic autoimmunity

ES评分 0 浏览量：250 下载量：0

DOI	10.1097/IN9.0000000000000056
刊名	Immunometabolism IJ
年，卷(期)	2025, 7(1)
作者	Pan, Wenliang; Tsokos, Maria G.; Li, Wei; Tsokos, George C.,
作者单位	Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA;
摘要	Protein phosphatases play a critical role in maintaining immune homeostasis by regulating various signaling pathways involved in immune cell activation, differentiation, and function. In the context of systemic autoimmune diseases, dysregulation of phosphatase activity contributes to aberrant immune responses, leading to chronic inflammation and tissue damage. This review explores the role of key phosphatases from the protein serine/threonine phosphatase and protein tyrosine phosphatase families that are implicated in systemic autoimmunity. We discuss their diverse roles in immune cell subsets, the mechanisms by which their dysregulation drives autoimmune pathogenesis, and the therapeutic potential of targeting these enzymes.
Abstract	Protein phosphatases play a critical role in maintaining immune homeostasis by regulating various signaling pathways involved in immune cell activation, differentiation, and function. In the context of systemic autoimmune diseases, dysregulation of phosphatase activity contributes to aberrant immune responses, leading to chronic inflammation and tissue damage. This review explores the role of key phosphatases from the protein serine/threonine phosphatase and protein tyrosine phosphatase families that are implicated in systemic autoimmunity. We discuss their diverse roles in immune cell subsets, the mechanisms by which their dysregulation drives autoimmune pathogenesis, and the therapeutic potential of targeting these enzymes.
关键词	phosphatase; autoimmunity; PP2A; TC-PTP; SHP1; SHP2; PTPN22; DUSP22; CD45; DUSP2
KeyWord	phosphatase; autoimmunity; PP2A; TC-PTP; SHP1; SHP2; PTPN22; DUSP22; CD45; DUSP2
基金项目
页码	-

参考文献
相关文献

[1]. Chen MJ, Dixon JE, Manning G. Genomics and evolution of protein phosphatases. Sci Signal. 2017;10(474):eaag1796.

[2]. Alonso A, Pulido R. The extended human PTPome: a growing tyrosine phosphatase family. FEBS J. 2016;283(8):1404-29.

[3]. Brautigan DL, Shenolikar S. Protein serine/threonine phosphatases: keys to unlocking regulators and substrates. Annu Rev Biochem. 2018;87:921-64.

[4]. Fowle H, Zhao Z, Grana X. PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer. Adv Cancer Res. 2019;144:55-93.

[5]. Seifried A, Schultz J, Gohla A. Human HAD phosphatases: structure, mechanism, and roles in health and disease. FEBS J. 2013;280(2):549-71.

[6]. Katsiari CG, Kyttaris VC, Juang YT, et al. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest. 2005;115(11):3193-204.

[7]. Tan W, Sunahori K, Zhao J, et al.; BIOLUPUS Network. Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis Rheum. 2011;63(9):2755-63.

[8]. Sunahori K, Juang YT, Kyttaris VC, et al. Promoter hypomethylation results in increased expression of protein phosphatase 2A in T cells from patients with systemic lupus erythematosus. J Immunol. 2011;186(7):4508-17.

[9]. Juang YT, Wang Y, Jiang G, et al. PP2A dephosphorylates Elf-1 and determines the expression of CD3zeta and FcRgamma in human systemic lupus erythematosus T cells. J Immunol. 2008;181(5):3658-64.

[10]. Juang YT, Sumibcay L, Tolnay M, et al. Elf-1 binds to the FcR g promoter and suppresses its activity. J Immunol. 2007;179:4884-9.

[11]. Enyedy EJ, Nambiar MP, Liossis SN, et al. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44(5):1114-21.

[12]. Juang YT, Rauen T, Wang Y, et al. Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus. J Biol Chem. 2011;286(3):1795-801.

[13]. Sunahori K, Nagpal K, Hedrich CM, et al. The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients. J Biol Chem. 2013;288(30):21936-44.

[14]. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661-78.

[15]. Long SA, Cerosaletti K, Wan JY, et al. An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun. 2011;12(2):116-25.

[16]. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43(3):246-52.

[17]. Todd JA, Walker NM, Cooper JD, et al.; Genetics of Type 1 Diabetes in Finland. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39(7):857-64.

[18]. Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med. 2008;359(26):2767-77.

[19]. Christophi GP, Hudson CA, Gruber RC, et al. SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. Lab Invest. 2008;88(3):243-55.

[20]. Christophi GP, Panos M, Hudson CA, et al. Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab Invest. 2009;89(7):742-59.

[21]. Singh K, Deshpande P, Pryshchep S, et al. ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis. J Immunol. 2009;183(12):8258-67.

[22]. Bosse Y, Lamontagne M, Gaudreault N, et al. Early-onset emphysema in a large French-Canadian family: a genetic investigation. Lancet Respir Med. 2019;7(5):427-36.

[23]. Zhernakova A, Stahl EA, Trynka G, et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 2011;7(2):e1002004.

[24]. Narumi Y, Isomoto H, Shiota M, et al. Polymorphisms of PTPN11 coding SHP-2 as biomarkers for ulcerative colitis susceptibility in the Japanese population. J Clin Immunol. 2009;29(3):303-10.

[25]. Uehara T, Hosogaya N, Matsuo N, et al. Systemic lupus erythematosus in a patient with Noonan syndrome-like disorder with loose anagen hair 1: more than a chance association. Am J Med Genet A. 2018;176(7):1662-6.

[26]. Wang J, Mizui M, Zeng LF, et al. Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. J Clin Invest. 2016;126(6):2077-92.

[27]. Xiao P, Zhang H, Zhang Y, et al. Phosphatase Shp2 exacerbates intestinal inflammation by disrupting macrophage responsiveness to interleukin-10. J Exp Med. 2019;216(2):337-49.

[28]. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004;36(4):337-8.

[29]. Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004;75(3):504-7.

[30]. Orru V, Tsai SJ, Rueda B, et al.; Italian Collaborative Group. A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet. 2009;18(3):569-79.

[31]. Michou L, Lasbleiz S, Rat AC, et al.; European Consortium on Rheumatoid Arthritis Families. Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc Natl Acad Sci U S A. 2007;104(5):1649-54.

[32]. Rodriguez-Rodriguez L, Taib WR, Topless R, et al. The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian case-control samples. Arthritis Rheum. 2011;63(2):365-72.

[33]. Lees CW, Barrett JC, Parkes M, et al. New IBD genetics: common pathways with other diseases. Gut. 2011;60(12):1739-53.

[34]. Diaz-Gallo LM, Espino-Paisan L, Fransen K, et al. Differential association of two PTPN22 coding variants with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2011;17(11):2287-94.

[35]. Velaga MR, Wilson V, Jennings CE, et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves’ disease. J Clin Endocrinol Metab. 2004;89(11):5862-5.

[36]. Faizi M, Rochmah N, Soetjipto S, et al. Protein tyrosine phosphatase non-receptor type 22 C1858T gene polymorphism in children with Down syndrome and autoimmune thyroid diseases. Pediatr Med Chir. 2023;45(1). doi: 10.4081/pmc.2023.283.

[37]. Chuang HC, Chen YM, Hung WT, et al. Downregulation of the phosphatase JKAP/DUSP22 in T cells as a potential new biomarker of systemic lupus erythematosus nephritis. Oncotarget. 2016;7(36):57593-605.

[38]. Qian C, Chen J, Xu X, et al. Measurement of synovium and serum dual specificity phosphatase 22 level: their inter-correlation and potency as biomarkers in rheumatoid arthritis. J Clin Lab Anal. 2022;36(1):e24111.

[39]. Sun L, Tu J, Chen X, et al. JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response. J Clin Lab Anal. 2021;35(4):e23709.

[40]. Zhou R, Chang Y, Liu J, et al. JNK pathway-associated phosphatase/DUSP22 suppresses CD4(+) T-cell activation and Th1/Th17-cell differentiation and negatively correlates with clinical activity in inflammatory bowel disease. Front Immunol. 2017;8:781.

[41]. Shi X, Yang W, Wang N, et al. Circulating JNK pathway-associated phosphatase level correlates with decreased risk, activity, inflammation level and reduced clinical response to tumor necrosis factor-alpha inhibitor in Crohn disease patients. Medicine (Baltim). 2019;98(33):e16622.

[42]. E C, Fang Y, Wu S, et al. Dual specificity phosphatase 22 relates to skin lesion degree and biologics history, while its longitudinal elevation during treatment reflects better outcome in psoriasis patients. J Clin Lab Anal. 2022;36(2):e24199.

[43]. Chen MH, Chuang HC, Yeh YC, et al. Dual-specificity phosphatases 22-deficient T cells contribute to the pathogenesis of ankylosing spondylitis. BMC Med. 2023;21(1):46.

[44]. Takeuchi T, Pang M, Amano K, et al. Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol. 1997;109:20-6.

[45]. Jeffrey KL, Brummer T, Rolph MS, et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol. 2006;7(3):274-83.

[46]. Lu D, Liu L, Ji X, et al. The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation. Nat Immunol. 2015;16(12):1263-73.

[47]. Ruvolo PP. The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin. 2016;6:87-99.

[48]. Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell. 2009;139(3):468-84.

[49]. Zheng H, Qi Y, Hu S, et al. Identification of Integrator-PP2A complex (INTAC), an RNA polymerase II phosphatase. Science. 2020;370(6520):eabb5872.

[50]. Girbig M, Misiaszek AD, Muller CW. Structural insights into nuclear transcription by eukaryotic DNA-dependent RNA polymerases. Nat Rev Mol Cell Biol. 2022;23(9):603-22.

[51]. Zheng M, Li D, Zhao Z, et al. Protein phosphatase 2A has an essential role in promoting thymocyte survival during selection. Proc Natl Acad Sci U S A. 2019;116(25):12422-7.

[52]. Li R, Zhang C, Xie F, et al. Protein phosphatase 2A deficiency in macrophages increases foam cell formation and accelerates atherosclerotic lesion development. Front Cardiovasc Med. 2021;8:745009.

[53]. Sun L, Pham TT, Cornell TT, et al. Myeloid-specific gene deletion of protein phosphatase 2A magnifies MyD88- and TRIF-dependent inflammation following endotoxin challenge. J Immunol. 2017;198(1):404-16.

[54]. Crispin JC, Apostolidis SA, Rosetti F, et al. Cutting edge: protein phosphatase 2A confers susceptibility to autoimmune disease through an IL-17-dependent mechanism. J Immunol. 2012;188(8):3567-71.

[55]. Hedrich CM, Mabert K, Rauen T, et al. DNA methylation in systemic lupus erythematosus. Epigenomics. 2017;9(4):505-25.

[56]. Hedrich CM, Rauen T, Apostolidis SA, et al. Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc Natl Acad Sci U S A. 2014;111(37):13457-62.

[57]. Hedrich CM, Crispin JC, Tsokos GC. Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. Autoimmunity. 2014;47(4):234-41.

[58]. Hedrich CM, Crispin JC, Rauen T, et al. cAMP responsive element modulator (CREM) alpha mediates chromatin remodeling of CD8 during the generation of CD3+ CD4- CD8- T cells. J Biol Chem. 2014;289(4):2361-70.

[59]. Hedrich CM, Rauen T, Crispin JC, et al. cAMP-responsive element modulator alpha (CREMalpha) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3+CD4-CD8- T cells in health and disease. J Biol Chem. 2013;288(44):31880-7.

[60]. Hedrich CM, Crispin JC, Rauen T, et al. cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc Natl Acad Sci U S A. 2012;109(41):16606-11.

[61]. Hedrich CM, Rauen T, Kis-Toth K, et al. cAMP-responsive element modulator alpha (CREMalpha) suppresses IL-17F protein expression in T lymphocytes from patients with systemic lupus erythematosus (SLE). J Biol Chem. 2012;287(7):4715-25.

[62]. Hedrich CM, Tsokos GC. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol Med. 2011;17(12):714-24.

[63]. Apostolidis SA, Rauen T, Hedrich CM, et al. Protein phosphatase 2A enables expression of interleukin 17 (IL-17) through chromatin remodeling. J Biol Chem. 2013;288(37):26775-84.

[64]. Xu Q, Jin X, Zheng M, et al. Phosphatase PP2A is essential for T(H)17 differentiation. Proc Natl Acad Sci U S A. 2019;116(3):982-7.

[65]. Jiang Y, Jin X, Chi Z, et al. Protein phosphatase 2A propels follicular T helper cell development in lupus. J Autoimmun. 2023;136:103028.

[66]. Meidan E, Li H, Pan W, et al. Serine/threonine phosphatase PP2A is essential for optimal B cell function. JCI Insight. 2020;5(5):e130655.

[67]. Apostolidis SA, Rodriguez-Rodriguez N, Suarez-Fueyo A, et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol. 2016;17(5):556-64.

[68]. Sharabi A, Li H, Kasper IR, et al. PP2A enables IL-2 signaling by preserving IL-2Rbeta chain expression during Treg development. JCI Insight. 2019;5(9):e126294.

[69]. Ding Y, Yu A, Tsokos GC, et al. CD25 and protein phosphatase 2A cooperate to enhance IL-2R signaling in human regulatory T cells. J Immunol. 2019;203(1):93-104.

[70]. Crispin JC, Apostolidis SA, Finnell MI, et al. Induction of PP2A Bbeta, a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2011;108(30):12443-8.

[71]. Rodriguez-Rodriguez N, Madera-Salcedo IK, Cisneros-Segura JA, et al. Protein phosphatase 2A B55beta limits CD8+ T cell lifespan following cytokine withdrawal. J Clin Invest. 2020;130(11):5989-6004.

[72]. Pan W, Sharabi A, Ferretti A, et al. PPP2R2D suppresses IL-2 production and Treg function. JCI Insight. 2020;5(19):e138215.

[73]. Pan W, Scherlinger M, Yoshida N, et al. PPP2R2D suppresses effector T cell exhaustion and regulatory T cell expansion and inhibits tumor growth in melanoma. J Immunol. 2022;209(3):621-8.

[74]. Pan W, Nagpal K, Suarez-Fueyo A, et al. The regulatory subunit PPP2R2A of PP2A enhances Th1 and Th17 differentiation through activation of the GEF-H1/RhoA/ROCK signaling pathway. J Immunol. 2021;206(8):1719-28.

[75]. Pan W, Tsokos MG, Scherlinger M, et al. The PP2A regulatory subunit PPP2R2A controls NAD(+) biosynthesis to regulate T cell subset differentiation in systemic autoimmunity. Cell Rep. 2024;43(7):114379.

[76]. Muppirala M, Gupta V, Swarup G. Emerging role of tyrosine phosphatase, TCPTP, in the organelles of the early secretory pathway. Biochim Biophys Acta. 2013;1833(5):1125-32.

[77]. Spalinger MR, McCole DF, Rogler G, et al. Role of protein tyrosine phosphatases in regulating the immune system: implications for chronic intestinal inflammation. Inflamm Bowel Dis. 2015;21(3):645-55.

[78]. Jeanpierre M, Cognard J, Tusseau M, et al. Haploinsufficiency in PTPN2 leads to early-onset systemic autoimmunity from Evans syndrome to lupus. J Exp Med. 2024;221(9):e20232337.

[79]. You-Ten KE, Muise ES, Itie A, et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med. 1997;186(5):683-93.

[80]. Hassan SW, Doody KM, Hardy S, et al. Increased susceptibility to dextran sulfate sodium induced colitis in the T cell protein tyrosine phosphatase heterozygous mouse. PLoS One. 2010;5(1):e8868.

[81]. Svensson MN, Doody KM, Schmiedel BJ, et al. Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity. J Clin Invest. 2019;129(3):1193-210.

[82]. Wiede F, Sacirbegovic F, Leong YA, et al. PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity. J Autoimmun. 2017;76:85-100.

[83]. Wiede F, Brodnicki TC, Goh PK, et al. T-Cell-specific PTPN2 deficiency in NOD mice accelerates the development of type 1 diabetes and autoimmune comorbidities. Diabetes. 2019;68(6):1251-66.

[84]. Spalinger MR, Kasper S, Chassard C, et al. PTPN2 controls differentiation of CD4(+) T cells and limits intestinal inflammation and intestinal dysbiosis. Mucosal Immunol. 2015;8(4):918-29.

[85]. Yi Z, Lin WW, Stunz LL, et al. The adaptor TRAF3 restrains the lineage determination of thymic regulatory T cells by modulating signaling via the receptor for IL-2. Nat Immunol. 2014;15(9):866-74.

[86]. Hsieh WC, Svensson MN, Zoccheddu M, et al. PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis. JCI Insight. 2020;5(20):e141868.

[87]. Spalinger MR, Manzini R, Hering L, et al. PTPN2 regulates inflammasome activation and controls onset of intestinal inflammation and colon cancer. Cell Rep. 2018;22(7):1835-48.

[88]. Spalinger MR, Sayoc-Becerra A, Santos AN, et al. PTPN2 regulates interactions between macrophages and intestinal epithelial cells to promote intestinal barrier function. Gastroenterology. 2020;159(5):1763-77.e14.

[89]. Bussieres-Marmen S, Vinette V, Gungabeesoon J, et al. Loss of T-cell protein tyrosine phosphatase in the intestinal epithelium promotes local inflammation by increasing colonic stem cell proliferation. Cell Mol Immunol. 2018;15(4):367-76.

[90]. Lorenz U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev. 2009;228(1):342-59.

[91]. Pei D, Wang J, Walsh CT. Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1. Proc Natl Acad Sci U S A. 1996;93(3):1141-5.

[92]. Yang J, Liu L, He D, et al. Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem. 2003;278(8):6516-20.

[93]. Shultz LD, Sidman CL. Genetically determined murine models of immunodeficiency. Annu Rev Immunol. 1987;5:367-403.

[94]. Kozlowski M, Mlinaric-Rascan I, Feng GS, et al. Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice. J Exp Med. 1993;178(6):2157-63.

[95]. Shultz LD, Schweitzer PA, Rajan TV, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell. 1993;73(7):1445-54.

[96]. Deng C, Minguela A, Hussain RZ, et al. Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis. J Immunol. 2002;168(9):4511-8.

[97]. Croker BA, Lawson BR, Rutschmann S, et al. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc Natl Acad Sci U S A. 2008;105(39):15028-33.

[98]. Tartey S, Gurung P, Dasari TK, et al. ASK1/2 signaling promotes inflammation in a mouse model of neutrophilic dermatosis. J Clin Invest. 2018;128(5):2042-7.

[99]. Markovics A, Toth DM, Glant TT, et al. Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase. Arthritis Res Ther. 2020;22(1):160.

[100]. Gu Q, Tung KS, Lorenz UM. Treg-specific deletion of the phosphatase SHP-1 impairs control of inflammation in vivo. Front Immunol. 2023;14:1139326.

[101]. Khalil AM, Cambier JC, Shlomchik MJ. B cell receptor signal transduction in the GC is short-circuited by high phosphatase activity. Science. 2012;336(6085):1178-81.

[102]. Pao LI, Lam KP, Henderson JM, et al. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity. 2007;27(1):35-48.

[103]. Kaneko T, Saito Y, Kotani T, et al. Dendritic cell-specific ablation of the protein tyrosine phosphatase Shp1 promotes Th1 cell differentiation and induces autoimmunity. J Immunol. 2012;188(11):5397-407.

[104]. Abram CL, Roberge GL, Pao LI, et al. Distinct roles for neutrophils and dendritic cells in inflammation and autoimmunity in motheaten mice. Immunity. 2013;38(3):489-501.

[105]. Speir M, Nowell CJ, Chen AA, et al. Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation. Nat Immunol. 2020;21(1):54-64.

[106]. Moussavi-Harami SF, Cleary SJ, Magnen M, et al. Neutrophil-specific Shp1 loss results in lethal pulmonary hemorrhage in mouse models of acute lung injury. J Clin Invest. 2024;134(24):e183161.

[107]. Hof P, Pluskey S, Dhe-Paganon S, et al. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92(4):441-50.

[108]. Barford D, Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure. 1998;6(3):249-54.

[109]. Poole AW, Jones ML. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal. 2005;17(11):1323-32.

[110]. Maeshima K, Stanford SM, Hammaker D, et al. Abnormal PTPN11 enhancer methylation promotes rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and joint inflammation. JCI Insight. 2016;1(7):e86580.

[111]. Yamashita H, Kotani T, Park JH, et al. Role of the protein tyrosine phosphatase Shp2 in homeostasis of the intestinal epithelium. PLoS One. 2014;9(3):e92904.

[112]. Gregorieff A, Cloutier JF, Veillette A. Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). J Biol Chem. 1998;273(21):13217-22.

[113]. Bottini N, Peterson EJ. Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease. Annu Rev Immunol. 2014;32:83-119.

[114]. Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet. 2005;37(12):1317-9.

[115]. Rieck M, Arechiga A, Onengut-Gumuscu S, et al. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol. 2007;179(7):4704-10.

[116]. Arechiga AF, Habib T, He Y, et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol. 2009;182(6):3343-7.

[117]. Anderson W, Barahmand-Pour-Whitman F, Linsley PS, et al. PTPN22 R620W gene editing in T cells enhances low-avidity TCR responses. Elife. 2023;12:e81577.

[118]. Menard L, Saadoun D, Isnardi I, et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest. 2011;121(9):3635-44.

[119]. Schickel JN, Kuhny M, Baldo A, et al. PTPN22 inhibition resets defective human central B cell tolerance. Sci Immunol. 2016;1(1):aaf7153.

[120]. Hasegawa K, Martin F, Huang G, et al. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science. 2004;303(5658):685-9.

[121]. Maine CJ, Marquardt K, Cheung J, et al. PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells. J Immunol. 2014;192(4):1415-24.

[122]. Brownlie RJ, Miosge LA, Vassilakos D, et al. Lack of the phosphatase PTPN22 increases adhesion of murine regulatory T cells to improve their immunosuppressive function. Sci Signal. 2012;5(252):ra87.

[123]. Maine CJ, Hamilton-Williams EE, Cheung J, et al. PTPN22 alters the development of regulatory T cells in the thymus. J Immunol. 2012;188(11):5267-75.

[124]. Chang HH, Miaw SC, Tseng W, et al. PTPN22 modulates macrophage polarization and susceptibility to dextran sulfate sodium-induced colitis. J Immunol. 2013;191(5):2134-43.

[125]. Spalinger MR, Kasper S, Gottier C, et al. NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J Clin Invest. 2016;126(5):1783-800.

[126]. Lin X, Pelletier S, Gingras S, et al. CRISPR-Cas9-mediated modification of the NOD mouse genome with Ptpn22R619W mutation increases autoimmune diabetes. Diabetes. 2016;65(8):2134-8.

[127]. Holmes DA, Suto E, Lee WP, et al. Autoimmunity-associated protein tyrosine phosphatase PEP negatively regulates IFN-alpha receptor signaling. J Exp Med. 2015;212(7):1081-93.

[128]. Maine CJ, Marquardt K, Scatizzi JC, et al. The effect of the autoimmunity-associated gene, PTPN22, on a BXSB-derived model of lupus. Clin Immunol. 2015;156(1):65-73.

[129]. Lee J, Yurkovetskiy LA, Reiman D, et al. Androgens contribute to sex bias of autoimmunity in mice by T cell-intrinsic regulation of PTPN22 phosphatase expression. Nat Commun. 2024;15(1):7688.

[130]. Vermeren S, Miles K, Chu JY, et al. PTPN22 is a critical regulator of Fcgamma receptor-mediated neutrophil activation. J Immunol. 2016;197(12):4771-9.

[131]. Sood S, Brownlie RJ, Garcia C, et al. Loss of the protein tyrosine phosphatase PTPN22 reduces mannan-induced autoimmune arthritis in SKG mice. J Immunol. 2016;197(2):429-40.

[132]. Yokota T, Nara Y, Kashima A, et al. Crystal structure of human dual specificity phosphatase, JNK stimulatory phosphatase-1, at 1.5 A resolution. Proteins. 2007;66(2):272-8.

[133]. Huang CY, Tan TH. DUSPs, to MAP kinases and beyond. Cell Biosci. 2012;2(1):24.

[134]. Chen AJ, Zhou G, Juan T, et al. The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathway. J Biol Chem. 2002;277(39):36592-601.

[135]. Shen Y, Luche R, Wei B, et al. Activation of the JNK signaling pathway by a dual-specificity phosphatase, JSP-1. Proc Natl Acad Sci U S A. 2001;98(24):13613-8.

[136]. Li JP, Yang CY, Chuang HC, et al. The phosphatase JKAP/DUSP22 inhibits T-cell receptor signalling and autoimmunity by inactivating Lck. Nat Commun. 2014;5:3618.

[137]. Kralova J, Pavliuchenko N, Fabisik M, et al. The receptor-type protein tyrosine phosphatase CD45 promotes onset and severity of IL-1beta-mediated autoinflammatory osteomyelitis. J Biol Chem. 2021;297(4):101131.

[138]. Rohan PJ, Davis P, Moskaluk CA, et al. PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science. 1993;259(5102):1763-6.

[139]. Wei W, Jiao Y, Postlethwaite A, et al. Dual-specificity phosphatases 2: surprising positive effect at the molecular level and a potential biomarker of diseases. Genes Immun. 2013;14(1):1-6.

[140]. Dijkmans BA, van Rijthoven AW, Goei The HS, et al. Cyclosporine in rheumatoid arthritis. Semin Arthritis Rheum. 1992;2

引用本文

Pan, Wenliang; Tsokos, Maria G.; Li, Wei; Tsokos, George C.. Protein phosphatases in systemic autoimmunity [J]. Immunometabolism. 2025; 7; (1). - .

文献评论

相关学者

相关机构